A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD200 in Pediatric Subjects With Attention-Deficit Hyperactivity Disorder

Trial Profile

A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD200 in Pediatric Subjects With Attention-Deficit Hyperactivity Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2018

At a glance

  • Drugs Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms CEES
  • Sponsors Ironshore Pharmaceutical and Development
  • Most Recent Events

    • 09 Aug 2018 According to an Ironshore Pharmaceuticals and Development media release, the U.S. Food and Drug Administration has approved the New Drug Application for JORNAY PM for the treatment of Attention Deficit Hyperactivity Disorder in patients 6 years and older. Ironshore plans to initiate the commercial launch of JORNAY PM in the first half of 2019.
    • 15 Dec 2016 According to Ironshore Pharmaceutical media release, U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for HLD200 in the treatment of Attention-Deficit/Hyperactivity Disorder and expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is July 30, 2017.
    • 02 Oct 2015 According to a Highland Therapeutics media release, Ironshore Pharmaceuticals & Development will be presenting clinical data from this trial at the American Academy of Child and Adolescent Psychiatry
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top